Allogeneic CD19-CAR-T cell infusion after allogeneic hematopoietic stem cell transplantation in B cell malignancies

BackgroundAllogeneic hematopoietic stem cell transplantation (allo-HSCT) is considered the cornerstone in treatment of hematological malignancies. However, relapse of the hematological disease after allo-HSCT remains a challenge and is associated with poor long-term survival. Chimeric antigen receptor redirected T cells (CAR-T cells) can lead to disease remission in patients with relapsed/refractory hematological malignancies. However, the therapeutic window for infusion of CAR-T cells post allo-HSCT and its efficacy are debatable.Main bodyIn this review, we first discuss the use of CAR-T cells for relapsed cases after allo-HSCT. We then review the toxicities and the occurrence of graft-versus-host disease in relapsed patients who received CAR-T cells post allo-HSCT. Finally, we review clinical trial registrations and the therapeutic time window for infusion of CAR-T cells post allo-HSCT.ConclusionsThe treatment of allogeneic CAR-T cells is beneficial for patients with relapsed B cell malignancies after allo-HSCT with low toxicities and complications. However, multicenter clinical trials with larger sample sizes should be performed to select the optimal therapeutic window and confirm its efficacy.

• Publication year

  2017

• Venue

  Journal of Hematology & Oncology

• Publication date

  2017-01-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.1186/s13045-017-0405-3PMID 28143567PMCID 5282795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukemia

  2016cited by this paper
• Allogeneic T Cells That Express an Anti-CD19 Chimeric Antigen Receptor Induce Remissions of B-Cell Malignancies That Progress After Allogeneic Hematopoietic Stem-Cell Transplantation Without Causing Graft-Versus-Host Disease.

  2016cited by this paper
• 嵌合抗原受体T细胞治疗儿童急性B淋巴细胞白血病异基因造血干细胞移植后复发一例报告并文献复习

  2016cited by this paper
• Donor lymphocyte infusion after allogeneic stem cell transplantation.

  2016cited by this paper
• Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors.

  2016cited by this paper
• History of graft-versus-host disease.

  2016cited by this paper
• Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

  2016cited by this paper
• High rate of complete responses to immune checkpoint inhibitors in patients with relapsed or refractory Hodgkin lymphoma previously exposed to epigenetic therapy

  2016cited by this paper
• Minimal residual disease- and graft-vs.-host disease-guided multiple consolidation chemotherapy and donor lymphocyte infusion prevent second acute leukemia relapse after allotransplant

  2016cited by this paper
• Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy

  2016cited by this paper
• Co-infusion of haplo-identical CD19-chimeric antigen receptor T cells and stem cells achieved full donor engraftment in refractory acute lymphoblastic leukemia

  2016cited by this paper
• Blinatumomab may induce graft versus host leukemia in patients with pre‐B ALL relapsing after hematopoietic stem cell transplant

  2016cited by this paper
• Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.

  2016cited by this paper
• Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo

  2015cited by this paper
• CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015cited by this paper
• Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab

  2015cited by this paper
• Donor-derived CD19-targeted T cells in allogeneic transplants

  2015cited by this paper
• Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• Chimeric antigen receptor T cells for ALL.

  2015cited by this paper
• [Efficacy of Donor Lymphocyte Infusion for Treating Relapsed High-Risk Leukemia patients after Allogeneic Hematopoietic Stem Cell Transplantation].

  2015cited by this paper
• Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?

  2015cited by this paper
• Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

  2014cited by this paper
• Allogeneic chimeric antigen receptor-modified cells for adoptive cell therapy of cancer

  2014cited by this paper
• Cell-based strategies to manage leukemia relapse: efficacy and feasibility of immunotherapy approaches

  2014cited by this paper
• Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention?

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014influential reference
• Relapsed childhood acute lymphoblastic leukaemia.

  2013cited by this paper
• Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation.

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013influential reference
• Monitoring of minimal residual disease (MRD) is useful to predict prognosis of adult patients with Ph-negative ALL: results of a prospective study (ALL MRD2002 Study)

  2013cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• The myth of the second remission of acute leukemia in the adult.

  2013cited by this paper
• Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study.

  2013cited by this paper
• Where do we stand in the treatment of relapsed acute lymphoblastic leukemia?

  2012cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation

  2011influential reference
• Complete remission after blinatumomab-induced donor T-cell activation in three pediatric patients with post-transplant relapsed acute lymphoblastic leukemia

  2011cited by this paper
• Human Umbilical Cord Blood-derived Stromal Cells, a New Resource in the Suppression of Acute Graft-versus-host Disease in Haploidentical Stem Cell Transplantation in Sublethally Irradiated Mice*

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Combining CD19 redirection and alloanergization to generate tumor-specific human T cells for allogeneic cell therapy of B-cell malignancies.

  2010cited by this paper

• Long-Term Follow-Up of CD19 CAR-T Cell Therapy in Acute Lymphoblastic Leukemia Patients Relapsed After Allo-HSCT

  2026cites this paper
• Utilization of donor CLL-1 CAR-T cells for the treatment of relapsed of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation

  2025cites this paper
• Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution

  2025cites this paper
• CAR-NK cell therapy: promise and challenges in solid tumors

  2025cites this paper
• A Retrospective Study on the Role of Tranexamic Acid in Reverse Total Shoulder Arthroplasty for Trauma Patients With Complex Proximal Humerus Fractures

  2025cites this paper
• Advancements in adoptive CAR immune cell immunotherapy synergistically combined with multimodal approaches for tumor treatment

  2024cites this paper
• Enhancing CAR T cells function: role of immunomodulators in cancer immunotherapy

  2024cites this paper
• Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment.

  2024cites this paper
• Prophylactic donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation

  2024cites this paper
• A Review of Practice-Changing Therapies in Oncology in the Era of Personalized Medicine

  2024cites this paper
• PD-1 checkpoint inhibition enhances the antilymphoma activity of CD19-CAR-iNKT cells that retain their ability to prevent alloreactivity

  2024influential citation
• Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin's Lymphoma

  2024cites this paper
• CAR-T cell therapy in treating advanced prostate cancer

  2024influential citation
• GVHD after CAR T-cell therapy post allogeneic hematopoietic cell transplantation — successfully treated by extracorporeal photopheresis

  2024cites this paper
• Generating advanced CAR-based therapy for hematological malignancies in clinical practice: targets to cell sources to combinational strategies

  2024cites this paper
• Syngeneic Mouse Models for Pre-Clinical Evaluation of CAR T Cells

  2024cites this paper
• Autologous CD19-Targeted Chimeric Antigen Receptor (CAR)T-Cells as the Future of Systemic Lupus Erythematosus Treatment.

  2023cites this paper
• Optimizing CAR‐T cell therapy in adults with B‐cell acute lymphoblastic leukemia

  2023cites this paper
• Impact of GVHD on lymphoma progression: Nationwide study from Japanese Society for Transplantation and Cellular Therapy

  2023cites this paper
• The role of MSCs and CAR-MSCs in cellular immunotherapy

  2023cites this paper
• Donor-derived CAR-T therapy improves the survival of relapsed B-ALL after allogeneic transplantation compared with donor lymphocyte infusion

  2023cites this paper
• CAR-T cells therapy: a potential new strategy against prostate cancer

  2023cites this paper
• Donor Hematopoietic Stem Cell/Lymphocyte Maintenance Treatment After CAR T-Cell Therapy in Patients With B-Cell Acute Lymphoblastic Leukemia Relapse Following Stem Cell Transplant

  2023cites this paper
• Application of CAR‐T cell technology in autoimmune diseases and human immunodeficiency virus infection treatment

  2023cites this paper
• Chimeric antigen receptor T-cell therapy in acute myeloid leukemia

  2022cites this paper
• CD318 is a target of chimeric antigen receptor T cells for the treatment of colorectal cancer

  2022cites this paper
• Strategies to enhance CAR-T persistence

  2022cites this paper
• Toxicities following CAR-T therapy for hematological malignancies.

  2022cites this paper
• Waldenström Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies

  2022cites this paper
• Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies

  2022cites this paper
• Universal chimeric antigen receptor T cell therapy - The future of cell therapy: A review providing clinical evidence.

  2022cites this paper
• Advances in single-cell nanoencapsulation and applications in diseases

  2022cites this paper
• Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemia

  2022cites this paper
• Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies.

  2022cites this paper
• Donor T cells for CAR T cell therapy

  2022cites this paper
• Hurdles to breakthrough in CAR T cell therapy of solid tumors

  2022cites this paper
• Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting

  2022cites this paper
• Research Progress in Immunotherapy of Pancreatic Cancer

  2022cites this paper
• B-cell maturation antigen targeting strategies in multiple myeloma treatment, advantages and disadvantages

  2022cites this paper
• Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study

  2022cites this paper
• Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects

  2021cites this paper
• Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.

  2021cites this paper
• Re-Emergence of Minimal Residual Disease Detected by Flow Cytometry Predicts an Adverse Outcome in Pediatric Acute Lymphoblastic Leukemia

  2021cites this paper
• Genetic Mechanism of Leukemia Relapse Following CD19 Chimeric Antigen Receptor T Cell Therapy

  2021cites this paper
• Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies

  2021cites this paper
• 供者CD19 CAR-T细胞治疗急性B淋巴细胞白血病移植后复发九例临床观察

  2021cites this paper
• CAR-T after Stem Cell Transplantation in B-Cell Lymphoproliferative Disorders: Are They Really Autologous or Allogenic Cell Therapies?

  2021cites this paper
• Immunotherapeutic Potential of T Memory Stem Cells

  2021cites this paper
• The immunologic aspects of cytokine release syndrome and graft versus host disease following CAR T cell therapy

  2021cites this paper
• Pancreatic cancer in 2021: What you need to know to win

  2021cites this paper
• Новейшие тенденции в совершенствовании CAR-Т-клеточной терапии: от лейкозов к солидным злокачественным новообразованиям

  2021cites this paper
• Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities

  2021cites this paper
• A Deep Dive Into the Newest Avenues of Immunotherapy for Pediatric Osteosarcoma: A Systematic Review

  2021cites this paper
• The latest trends in improving CAR-T cell therapy: from leukemia to solid malignant tumors

  2021cites this paper
• Emerging Approaches for Solid Tumor Treatment Using CAR-T Cell Therapy

  2021cites this paper
• Dilemma and Challenge of Immunotherapy for Pancreatic Cancer

  2020cites this paper
• Anti-CD19 CAR-T therapy for EBV-negative posttransplantation lymphoproliferative disease—a single center case series

  2020cites this paper
• Low Level Donor Chimerism of CD19 CAR-T Cells Returned to Complete Donor Chimerism in Patients with Relapse After Allo-Hematopoietic Stem Cell Transplant

  2020cites this paper
• Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model.

  2020cites this paper
• Donor-derived CD19 CAR-T cell therapy of relapse of CD19-positive B-ALL post allotransplant

  2020cites this paper
• A Primer on CAR-T Therapy: What Does It Mean for Pathologists?: A Summary Guidance From the College of American Pathologists CAR-T Workgroup.

  2020cites this paper
• OTT_A_277146 11471..11484

  2020cites this paper
• Acute Graft-Versus-Host Disease After Humanized Anti-CD19-CAR T Therapy in Relapsed B-ALL Patients After Allogeneic Hematopoietic Stem Cell Transplant

  2020cites this paper
• 造血干细胞移植后复发急性B淋巴细胞白血病CD19 CAR-T细胞治疗后的维持治疗

  2020cites this paper
• Recent advances in CAR-T cell engineering

  2020cites this paper
• Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies

  2020cites this paper
• Chimeric Antigen Receptor Based Therapy as a Potential Approach in Autoimmune Diseases: How Close Are We to the Treatment?

  2020cites this paper
• CHIMERIC ANTIGEN RECEPTOR FOR CHRONIC LYMPHOCYTIC LEUKEMIA - A REVIEW

  2019cites this paper
• Les CAR T dans les hémopathies malignes : état des lieux, perspectives et mise en place dans la pratique clinique

  2019influential citation
• Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

  2019cites this paper
• The promise of chimeric antigen receptor (CAR) T cell therapy in multiple myeloma.

  2019cites this paper
• Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy.

  2019cites this paper
• Treatment Selection for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Era of Tyrosine Kinase Inhibitors

  2019cites this paper
• Preventive infusion of donor-derived CAR-T cells after haploidentical transplantation

  2019cites this paper
• Immunotherapeutic options for management of relapsed or refractory B-cell acute lymphoblastic leukemia: how to select newly approved agents?

  2019cites this paper
• Review of therapeutic approaches for B-cell malignancies with immune checkpoint blockade and chimeric antigen receptor t-cell therapies: Development, benefits, and limitations.

  2019cites this paper
• Haploidentical CD19/CD22 bispecific CAR-T cells induced MRD-negative remission in a patient with relapsed and refractory adult B-ALL after haploidentical hematopoietic stem cell transplantation

  2019cites this paper
• Recent perspective on CAR and Fcγ-CR T cell immunotherapy for cancers: Preclinical evidence versus clinical outcomes.

  2019cites this paper
• CRISPR/Cas9 guided genome and epigenome engineering and its therapeutic applications in immune mediated diseases.

  2019cites this paper
• Second allogeneic stem cell transplantation in patients with acute lymphoblastic leukaemia: a study on behalf of the Acute Leukaemia Working Party of the European Society for Blood and Marrow Transplantation

  2019cites this paper
• Study on the Prognostic Value of Aberrant Antigen in Patients With Acute B Lymphocytic Leukemia.

  2019cites this paper
• Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation

  2019cites this paper
• Use of chimeric antigen receptor T cells in allogeneic hematopoietic stem cell transplantation.

  2019cites this paper
• Haploidentical Stem Cell Transplantation With Post-Transplantation Cyclophosphamide for Aggressive Lymphomas: How Far Have We Come and Where Are We Going?

  2019cites this paper
• Clinical trials of dual-target CAR T cells, donor-derived CAR T cells, and universal CAR T cells for acute lymphoid leukemia

  2019cites this paper
• Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia

  2018cites this paper
• The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma

  2018cites this paper
• The functional verification of EGFR-CAR T-cells targeted to hypopharyngeal squamous cell carcinoma

  2018cites this paper
• CART cells are prone to Fas- and DR5-mediated cell death

  2018cites this paper
• Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

  2018cites this paper
• Donor-derived CAR-T Cells Serve as a Reduced-intensity Conditioning Regimen for Haploidentical Stem Cell Transplantation in Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: Case Report and Review of the Literature

  2018cites this paper
• Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia in the Era of Novel Therapies

  2018cites this paper
• Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells

  2018influential citation
• Genetically enhanced T lymphocytes and the intensive care unit

  2018cites this paper
• Epidemiology and biology of relapse after stem cell transplantation

  2018cites this paper
• CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies

  2018cites this paper
• Concise Review: Human Pluripotent Stem Cells to Produce Cell‐Based Cancer Immunotherapy

  2018cites this paper
• DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells

  2018cites this paper
• Chimeric antigen receptor T cells: a novel therapy for solid tumors

  2017cites this paper
• CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.

  2017cites this paper